ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ and Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leukemia & lymphoma. England: Informa Healthcare, 2012, vol. 53, No 8, p. 1627-1629. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.656104. |
Other formats:
BibTeX
LaTeX
RIS
@article{979222, author = {Šimara, Pavel and Peterková, Martina and Stejskal, Stanislav and Potěšilová, Michaela and Krontorád Koutná, Irena and Ráčil, Zdeněk and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Mayer, Jiří}, article_location = {England}, article_number = {8}, doi = {http://dx.doi.org/10.3109/10428194.2012.656104}, keywords = {p-CrkL; chronic myeloid leukemia; imatinib}, language = {eng}, issn = {1042-8194}, journal = {Leukemia & lymphoma}, title = {BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.}, url = {http://www.ncbi.nlm.nih.gov/pubmed/22233112}, volume = {53}, year = {2012} }
TY - JOUR ID - 979222 AU - Šimara, Pavel - Peterková, Martina - Stejskal, Stanislav - Potěšilová, Michaela - Krontorád Koutná, Irena - Ráčil, Zdeněk - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Mayer, Jiří PY - 2012 TI - BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. JF - Leukemia & lymphoma VL - 53 IS - 8 SP - 1627-1629 EP - 1627-1629 PB - Informa Healthcare SN - 10428194 KW - p-CrkL KW - chronic myeloid leukemia KW - imatinib UR - http://www.ncbi.nlm.nih.gov/pubmed/22233112 L2 - http://www.ncbi.nlm.nih.gov/pubmed/22233112 N2 - In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome. ER -
ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ and Jiří MAYER. BCR-ABL activity measured by 50\%{} inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. \textit{Leukemia \&{} lymphoma}. England: Informa Healthcare, 2012, vol.~53, No~8, p.~1627-1629. ISSN~1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.656104.
|